274 related articles for article (PubMed ID: 24457369)
1. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
Julien S; Biesemeier A; Taubitz T; Schraermeyer U
Br J Ophthalmol; 2014 Jun; 98(6):813-25. PubMed ID: 24457369
[TBL] [Abstract][Full Text] [Related]
2. The effects of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys.
Ludinsky M; Christner S; Su N; Taubitz T; Tschulakow A; Biesemeier A; Julien-Schraermeyer S; Schraermeyer U
Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1117-25. PubMed ID: 27106625
[TBL] [Abstract][Full Text] [Related]
3. Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes.
Schraermeyer U; Julien S
Expert Opin Biol Ther; 2013 Feb; 13(2):157-67. PubMed ID: 23190450
[TBL] [Abstract][Full Text] [Related]
4. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
Tschulakow A; Christner S; Julien S; Ludinsky M; van der Giet M; Schraermeyer U
PLoS One; 2014; 9(11):e113701. PubMed ID: 25415380
[TBL] [Abstract][Full Text] [Related]
5. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation.
Blaauwgeers HG; Holtkamp GM; Rutten H; Witmer AN; Koolwijk P; Partanen TA; Alitalo K; Kroon ME; Kijlstra A; van Hinsbergh VW; Schlingemann RO
Am J Pathol; 1999 Aug; 155(2):421-8. PubMed ID: 10433935
[TBL] [Abstract][Full Text] [Related]
6. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
Klettner A; Recber M; Roider J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
[TBL] [Abstract][Full Text] [Related]
8. Penetration of bevacizumab through the retina after intravitreal injection in the monkey.
Heiduschka P; Fietz H; Hofmeister S; Schultheiss S; Mack AF; Peters S; Ziemssen F; Niggemann B; Julien S; Bartz-Schmidt KU; Schraermeyer U;
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2814-23. PubMed ID: 17525217
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
10. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid.
Kim IK; Husain D; Michaud N; Connolly E; Lane AM; Durrani K; Hafezi-Moghadam A; Gragoudas ES; O'Neill CA; Beyer JC; Miller JW
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):357-63. PubMed ID: 16384985
[TBL] [Abstract][Full Text] [Related]
12. In vitro induction of protein complexes between bevacizumab, VEGF-A¹⁶⁵ and heparin: explanation for deposits observed on endothelial veins in monkey eyes.
Julien S; Biesemeier A; Schraermeyer U
Br J Ophthalmol; 2013 Apr; 97(4):511-7. PubMed ID: 23355530
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal anatomical response of retinal-choroidal anastomosis to anti-vascular endothelial growth factor therapy.
Querques G; Rousseau A; Forte R; Scemama C; Caillaux V; Querques L; Souied EH
Retina; 2012 Mar; 32(3):458-67. PubMed ID: 21926939
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
15. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
16. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.
Peters S; Heiduschka P; Julien S; Ziemssen F; Fietz H; Bartz-Schmidt KU; ; Schraermeyer U
Am J Ophthalmol; 2007 Jun; 143(6):995-1002. PubMed ID: 17449002
[TBL] [Abstract][Full Text] [Related]
17. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
18. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.
Lassota N; Prause JU; Scherfig E; Kiilgaard JF; la Cour M
Acta Ophthalmol; 2010 May; 88(3):300-8. PubMed ID: 19416113
[TBL] [Abstract][Full Text] [Related]
19. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
Schnichels S; Hagemann U; Januschowski K; Hofmann J; Bartz-Schmidt KU; Szurman P; Spitzer MS; Aisenbrey S
Br J Ophthalmol; 2013 Jul; 97(7):917-23. PubMed ID: 23686000
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
